[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"National Medical Research Center for Therapy and Preventive Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":221},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,79,114,142,167,189],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100637475","epicardial-fat-tissue-and-cardiometabolic-risk-in-russian-and-asian-populations-100637475",false,"NCT07604610","Epicardial Fat Tissue and Cardiometabolic Risk in Russian and Asian Populations","Epicardial Fat Tissue Assessed by Echocardiography in Russian and Asian Populations: Association With Chronic Non-Communicable Diseases and Risk Factors","EPIGRAPH","Inclusion Criteria:\n\n* Patients aged 50-70 years undergoing transthoracic echocardiography in inpatient or outpatient settings;\n* Ability and willingness to provide informed consent.\n\nExclusion Criteria:\n\n* Refusal to sign informed consent;\n* Inability to perform transthoracic echocardiography or poor image quality;\n* Severe psychiatric disorders.","ALL","50 Years","70 Years",{"count":21,"type":22},500,"ESTIMATED","OBSERVATIONAL","Visceral obesity is a well-established risk factor for the development of chronic non-communicable diseases (NCDs). Epicardial fat tissue (EFT) is located on the surface of the myocardium and may directly affect cardiac function and contribute to structural and functional remodeling.\n\nAccording to the literature, increased EFT thickness is associated with a wide range of NCDs, disease severity, and prognosis.\n\nThe aim of this study is to investigate the associations between EFT thickness and clinical and anamnestic parameters, as well as to evaluate the prognostic value of this parameter in patients aged 50-70 years from the Russian Federation, Kazakhstan, Uzbekistan, and Kyrgyzstan.",[26,27,28],"Epicardial Fat Tissue (EFT)","Chronic Non-Communicable Diseases (NCDs)","Visceral Obesity",[30,31,32,33,34],"epicardial fat","echocardiography","cardiovascular risk","metabolic disorders","cohort study","RECRUITING","2026-05-18",{"date":38,"type":39},"2026-05-22","ACTUAL",{"date":41,"type":39},"2026-05-04",{"date":43,"type":22},"2028-03",{"name":45,"class":46},"National Medical Research Center for Therapy and Preventive Medicine","OTHER_GOV",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":58,"conditions":59,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":47},"100639683","clot-less---closure-tailored-less-antithrombotic-strategy-after-laac-for-stroke-prevention-100639683","NCT07575867","CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention","CLOT-LESS","Inclusion Criteria:\n\n* Age ≥18 years;\n* Documented nonvalvular AF (≥30 seconds on ECG within previous 12 months);\n* CHA2DS2-VASc score ≥3 for women and ≥2 for men;\n* Signed informed consent to participate in the study;\n\nExclusion Criteria:\n\n* Active indication for anticoagulation OTHER than atrial fibrillation at the time of enrollment and\u002For the predicted\u002Funpredicted occurrence of such indications during the entire study period (e.g., mechanical valve, acute VTE, recent PE requiring \\>3 months anticoagulation);\n* Inability to tolerate at least 3 months of apixaban therapy (for LAAC arm);\n* Indications for antiplatelet therapy or therapy with P2Y12 inhibitors at the time of inclusion and\u002For the predicted\u002Funpredicted occurrence of such indications during the entire study period;\n* The presence of mechanical prosthetic heart valves, mitral stenosis of severe or moderate degree;\n* Active DVT requiring anticoagulation;\n* Congenital or acquired haemostasis disorders, rheumatic heart disease or recurrent deep vein thrombosis;\n* Left ventricular ejection fraction (LVEF) \\\u003C 30%;\n* Glomerular filtration rate (GFR) \\\u003C 30 ml\u002Fmin (stage IV or V chronic kidney disease) or dialysis patient;\n* Severe liver failure, including cirrhosis and Child-Pugh Class C\u002FD;\n* NYHA class IV congestive heart failure;\n* The patient had a myocardial infarction - MI with or without ST segment elevation (STEMI, NSTEMI) with or without intervention, within 30 days before LAAC;\n* The patient had a stroke (of any cause, ischemic or hemorrhagic) within 30 days before LAAC;\n* Intracardiac thrombus before LAAC;\n* Major bleeding according to BARC criteria (type 3 and higher) within 30 days before LAAC or before randomization;\n* Amyloid cardiomyopathy;\n* Platelet count \\\u003C 100,000 x 109\u002Fl;\n* The patient participates in another study, with the exception of observational studies without therapeutic interventions;\n* Pregnant or breast-feeding patients, patients planning pregnancy during the study period;\n* The LAAC procedure was unsuccessful or interrupted for technical reasons;\n* PDL (peridevice leak) ≥ 3 mm;\n* Contraindications for one of the treatment regimens prescribed by the study protocol (including allergic reactions);\n* Planned cardiac or non-cardiac surgical procedure within 30 days before or 90 days after LAAC. Minor procedures not requiring discontinuation of antithrombotic therapy are permitted (e.g., cardioversion, catheter ablation, cataract surgery);\n* The patient has a heart tumor, active infection, signs of physiological tamponade;\n* The documented life expectancy of the patient is less than 12 months;","18 Years",{"count":57,"type":22},464,"This is a prospective, non-randomized, observational cohort study conducted at the FSBI \"NMRC TPM\" of the Ministry of Healthcare of the Russian Federation. Left atrial appendage closure (LAAC) has been shown to be non-inferior to oral anticoagulation for preventing cardioembolic events in patients with atrial fibrillation. However, the optimal post-procedural antithrombotic regimen following LAAC remains unclear, with no consensus on evidence-based therapy. Given current trends in cardiology favoring reduced-intensity antithrombotic strategies, this study aims to contribute to the evidence base by evaluating whether LAAC followed by reduced-dose apixaban (2.5 mg BID) for 3 months with subsequent complete withdrawal of antithrombotic therapy is superior to long-term standard-dose DOAC therapy in patients with non-valvular atrial fibrillation.",[60,61,62,63,64,65,66],"Atrial Fibrillation","Stroke Prevention in Patients With Atrial Fibrillation","Left Atrial Appendage Closure","Hemorrhage","Anticoagulants \u002F Administration & Dosage","Reduced-dose Apixaban","Thromboembolism",[68,69,70,71],"atrial fibrillation","left atrial appendage closure","anticoagulants","reduced dose apixaban",{"date":73,"type":39},"2026-05-08",{"date":75,"type":22},"2026-04",{"date":77,"type":22},"2032-04",{"name":45,"class":46},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":99,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":47},"100638369","effects-of-short-and-long-courses-of-intermittent-hypoxic-hyperoxic-training-in-patients-with-type-2-diabetes-including-elderly-100638369","NCT07574333","Effects of Short and Long Courses of Intermittent Hypoxic-Hyperoxic Training in Patients With Type 2 Diabetes Including Elderly","A Single-Center Randomized Clinical Trial With Prospective Follow-up of the Efficacy and Safety of Short and Long Duration Intermittent Hypoxic-Hyperoxic Training in Patients With Type 2 Diabetes Mellitus Including Elderly Patients","EFIR","Inclusion Criteria:\n\n* Age 50-74 years inclusive\n* Type 2 diabetes mellitus confirmed by medical documentation\n* Stable therapy for diabetes and other chronic diseases for at least 4 weeks prior to enrollment\n* Ability to comply with study protocol requirements\n* Signed informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Acute diabetes complications within 6 months (diabetic ketoacidosis, hyperosmolar hyperglycemic state, lactic acidosis, hypoglycemic coma)\n* Acute or active chronic infections\n* Angina pectoris functional class III-IV\n* Uncontrolled grade 3 arterial hypertension (SBP ≥180 and\u002For DBP ≥110 mmHg)\n* Acute cerebrovascular accident, myocardial infarction, surgical interventions, clinically significant injuries within 6 months\n* Internal carotid artery stenosis \\>60% and\u002For symptomatic stenosis 50-99%\n* Chronic obstructive pulmonary disease and bronchial asthma\n* Exacerbation and decompensation of chronic diseases within 1 month ALT and\u002For AST levels \\>2-3 times upper limit of normal\n* Congenital heart and major vessel abnormalities\n* Implanted cardiac pacemaker\n* Cancer with remission \\\u003C5 years\n* Mental illness, drug addiction, alcohol dependence\n* Pregnancy\n* Inability to participate throughout the study period","74 Years",{"count":89,"type":22},250,"INTERVENTIONAL",[92],"NA","This is a single-center randomized controlled trial evaluating the efficacy and safety of short (3 days) versus long (10 days) courses of intermittent hypoxic-hyperoxic training (IHHT) in patients with type 2 diabetes mellitus aged 50-74 years. Participants will be randomized into three groups: 3-day IHHT course (n≥100), 10-day IHHT course (n≥100), or control group receiving gas mixture with constant O2 21% for 10 days (n≥50). The primary outcomes are fasting glucose levels and HbA1c. Secondary outcomes include cardiovascular parameters, quality of life, cognitive function, and biological age.",[95,96,97,98],"Type 2 Diabetes Mellitus (T2DM)","Hyperglycemia","Metabolic Syndrome","Older Adults (65 Years and Older)",[100,101,102,103,104,105,106],"Intermittent hypoxic-hyperoxic training","T2DM","Type 2 Diabetes Mellitus","Glycemic control","Elderly patients","Non-pharmacological intervention","Hypoxia conditioning",{"date":108,"type":39},"2026-05-07",{"date":110,"type":39},"2025-10-15",{"date":112,"type":22},"2027-12-15",{"name":45,"class":46},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100621808","heart-failure-with-preserved-ejection-fraction-in-patients-with-hronic-obstructive-pulmonary-disease-clinical-course-and-prognosis-100621808","NCT07375433","Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course and Prognosis","HIPSTER","Inclusion Criteria:\n\n1. Verified diagnosis of COPD;\n2. Patients hospitalized with COPD;\n3. Citizenship of the Russian Federation;\n4. Patients aged 50 to 70 years;\n5. Patient consent to participate in the study.\n\nExclusion Criteria:\n\n1. Lack of Russian Federaion citizenship;\n2. Patient's refusal to participate in the study;\n3. Any chronic diseases, other than COPD, that affect the prognosis, in the acute and\u002For decompensated stage;\n4. Mental disorders.",{"count":122,"type":22},200,"Study aim is comparison of heart failire with preserved ejection fraction (HFpEF) detection rate in patients with Сhronic Obstructive Pulmonary Disease (COPD) and the clinical course and prognosis in patients with COPD depending on HFpEF presence.",[125,126],"COPD (Chronic Obstructive Pulmonary Disease)","Heart Failure With Preserved Ejection Fraction (HFpEF; Diagnosis)",[128,129,130,131,132],"Heart failure","Heart failure with Preserved Ejection Fraction","Biomarkers","COPD","Prognosis","2026-02-07",{"date":135,"type":39},"2026-02-10",{"date":137,"type":39},"2026-01-01",{"date":139,"type":22},"2026-12-31",{"name":45,"class":46},2,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":148,"sex":149,"minAge":55,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":90,"phases":153,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":47},"100613755","the-influence-of-beetroot-powder-at-a-dose-of-20-g-on-blood-pressure-microcirculation-and-biochemical-markers-in-men-with-arterial-hypertensionsvekla2025-100613755","NCT07270718","The Influence of Beetroot Powder at a Dose of 20 g on Blood Pressure, Microcirculation, and Biochemical Markers in Men With Arterial Hypertension.SVEKLA2025.","Inclusion Criteria:\n\n* A history of hypertension with achievement of the target blood pressure level according to the SMAD while taking regular AGT;\n* signing informed consent to participate in the study.\n\nExclusion Criteria:\n\n* coronary heart disease, including angina pectoris and myocardial infarction; cerebrovascular disease, including acute cerebrovascular accident and transient ischemic attack; obliterating atherosclerosis of peripheral vessels, revascularization in any vascular basin; cardiomyopathy; secondary forms of hypertension; type 1 or 2 diabetes mellitus, impaired glucose tolerance; inflammatory bowel diseases; organ transplantation; oncological, mental illnesses; diffuse connective tissue diseases in the anamnesis;\n* BMI ≥30 kg\u002Fm2;\n* symptoms of heart failure;\n* acute infectious diseases at the time of inclusion in the study and within 1 month prior to inclusion in the study;\n* Exacerbation of chronic non-communicable diseases;\n* alcoholism, taking narcotic drugs;\n* allergic and undesirable reactions to foods containing beetroot and egg white in the anamnesis;\n* refusal to continue participating in the study",true,"MALE","60 Years",{"count":152,"type":22},60,[92],"Objective: to evaluate the effectiveness of using a food product, dry finely dispersed beetroot powder in a dose of 20 g, containing 800 mg of nitrate (NO3-), in relation to the regulation of blood pressure in men with hypertension who reached the target blood pressure level while taking optimal antihypertensive therapy.\n\nCharacteristics of the study: randomized, open, and cross-sectional. Relevance of the study Currently, it is recognized that vasodilatory endothelial dysfunction due to impaired synthesis and bioavailability of endogenous nitric oxide (NO) is a characteristic change in patients with arterial hypertension (AH) and plays one of the key roles in the development and progression of this pathology.\n\nNitrate (NO3-), contained in food products, the highest content of which is found in beetroot, is converted into NO in the body after consumption, which can have a positive effect on the state of the cardiovascular system and lead to a decrease in blood pressure. Indeed, this assumption has been confirmed in various clinical studies. The results of the conducted studies demonstrate the positive effect of beetroot juice enriched with NO3- on the functional parameters of the cardiovascular system, in particular, the level of SAD and DBP, vasodilator function, endothelium and arterial stiffness, both in patients with hypertension and conditionally healthy people.\n\nHowever, most of the studies conducted in this field either include a relatively small number of subjects with hypertension, or do not have a cross-sectional design, which is a limitation in formulating unambiguous conclusions about the positive effect of taking beetroot enriched with NO3- on lowering blood pressure in this category of patients. Moreover, the effect of beetroot juice on the functional state of the peripheral arterial bed (terminal muscular arteries, distributive and precapillary arterioles) remains unexplored, which, due to the increased bioavailability of NO by the vascular wall, may be expressed in a decrease in arterial stiffness, a decrease in smooth muscle cell tone (MMC) and a decrease in total peripheral vascular resistance, which will have a positive effect on tissue homeostasis. It is relevant to study the effect of course intake of beetroot enriched with NO3- on the functional state of all arterial links and regulation of blood pressure in patients with hypertension.\n\nResearch materials and methods The study will be performed on the basis of the Laboratory of Microcirculation and Regional Blood Circulation of the Department of Fundamental and Applied Aspects of Obesity and the Center for Coordination of Fundamental Scientific Activities of the Federal State Budgetary Institution \"NMIC TPM\" of the Ministry of Health of the Russian Federation. The study is planned to include 60 men aged 18-60 years with hypertension who reached the target blood pressure level according to office measurement and daily blood pressure monitoring (SMAD) on the background of regular intake of AGT.\n\nResearch design The study will consist of two screening stages and one main stage (Figure 1). Patients will be divided into 2 equal groups of 30 men using simple randomization using the closed envelope method. The first group will be assigned a one-week course of daily intake of dry fine beetroot powder in a dose of 20 g containing 800 mg of NO3- (food product), the second group will continue regular intake of AGT. After 7 days, the crossing will be performed: patients of the first group will continue to receive regular AGT, and patients of the second group will receive a food product. At each stage, all participants undergo blood pressure and heart rate (HR) measurements, anthropometry, basic research methods\\* and SMAD. The total duration of the study will be 14-16 days.",[156],"Hypertensive Heart Disease Without (Congestive) Heart Failure",[158],"exogenous nitrate, nitric oxide, blood pressure, endothelial dysfunction, beetroot","2025-11-26",{"date":161,"type":39},"2025-12-08",{"date":163,"type":39},"2025-01-24",{"date":165,"type":22},"2026-12",{"name":45,"class":46},{"id":168,"slug":169,"hasResults":11,"nctId":170,"briefTitle":171,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":90,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":47},"100591744","efficacy-and-safety-of-a-beet-derived-inorganic-nitrate-based-food-product-for-the-prevention-of-contrast-induced-nephropathy-in-high-risk-patients-undergoing-percutaneous-coronary-intervention-100591744","NCT06984406","Efficacy and Safety of a Beet-Derived Inorganic Nitrate-Based Food Product for the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing Percutaneous Coronary Intervention","Randomized Controlled Trial on the Efficacy and Safety of a Beet-Derived Inorganic Nitrate-Based Food Product for the Prevention of Contrast-Induced Nephropathy in High-Risk Patients Undergoing Percutaneous Coronary Intervention (BEET-CIN Trial)","BEET-CIN","Inclusion Criteria:\n\n* Age ≥18 years.\n* Planned PCI.\n* High risk of CIN with:\n\n  1. eGFR according to the CKD-EPI formula \\\u003C60 ml\u002Fmin\u002F1.73 m2 or\n  2. At least two of the following criteria: liver damage (cirrhosis), diabetes mellitus, age \\>70 years, administration of contrast in the last 7 days, CHF (LVEF \\>40%), intake of drugs affecting renal function (ACE inhibitors, ARBs, NSAIDs, aminoglycosides, diuretics).\n* Signing informed consent.\n\nExclusion Criteria:\n\n* Allergy to nitrates.\n* Acute coronary syndrome.\n* Acute condition accompanied by systolic blood pressure \\\u003C90 mmHg for more th an 30 minutes or requiring the use of drugs with a positive inotropic effect.\n* Life-threatening conditions requiring emergency medical care.\n* Participation in other clinical trials.\n* Pregnancy, lactation.\n* Use of nitrates in the last 30 days.\n* Abuse of alcohol, illegal drugs, mnestic-intellectual decline, as well as other reasons and circumstances indicating expected low adherence to treatment.\n* Refusal to follow the plan of visits and examinations provided for by the protocol of this clinical trial.\n* Refusal to sign informed consent.\n* Infectious diseases.",{"count":176,"type":22},88,[92],"Contrast-induced nephropathy (CIN) is a common complication in high-risk patients undergoing percutaneous coronary intervention (PCI) due to exposure to iodinated contrast agents. CIN is associated with increased morbidity, prolonged hospital stays, and higher healthcare costs. Current preventive strategies include adequate hydration and minimizing contrast volume; however, there is no universally effective pharmacological intervention.\n\nRecent studies suggest that inorganic nitrates can enhance renal perfusion, reduce oxidative stress, and improve endothelial function, potentially lowering the risk of CIN. This study aims to evaluate the efficacy and safety of a beet-derived inorganic nitrate-based food product for the prevention of CIN in high-risk patients undergoing PCI.\n\nThis is a randomized, controlled, open-label clinical trial comparing two groups:\n\n1. Intervention Group: Patients receiving the beet-derived inorganic nitrate-based food product for 5 days (starting 24 hours before PCI).\n2. Control Group: Patients receiving standard medical care without additional nitrate supplementation.\n\nWe hypothesize that the nitrate-based food product will significantly reduce the incidence of CIN compared to standard care. Additionally, we expect:\n\n1. A lower increase in kidney injury biomarkers (NGAL, cystatin C) in the intervention group.\n2. A slower decline or even improvement in eGFR at follow-up.\n3. A potential reduction in MACE due to the vasoprotective effects of nitrates.\n4. Improved quality of life scores (EQ-5D) in the intervention group. If successful, this study will provide new evidence supporting the use of dietary nitrates for renal protection and may contribute to the development of novel, cost-effective prevention strategies for CIN.",[180],"Contrast-induced Nephropathy Following Percutaneous Intervention (CIN)","2025-05-14",{"date":183,"type":39},"2025-05-22",{"date":185,"type":39},"2025-04-01",{"date":187,"type":22},"2026-03",{"name":45,"class":46},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":196,"minAge":150,"maxAge":87,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":47},"100577865","association-of-heterogeneous-circulating-biomarkers-and-anamnestic-factors-of-pregnancy-adverse-course-and-outcomes-with-the-prognosis-of-heart-failure-with-preserved-ejection-fraction-100577865","NCT06803849","Association of Heterogeneous Circulating Biomarkers and Anamnestic Factors of Pregnancy Adverse Course and Outcomes With the Prognosis of Heart Failure With Preserved Ejection Fraction","CARPO-HF","Inclusion Criteria:\n\n* Women aged 60-74 years\n* Heart failure with preserved ejection fraction (diagnosed by using HFA-PEFF algorithm)\n* History of pregnancy with duration at least 20 weeks\n* Willing and legally able to sign informed consent\n\nExclusion Criteria:\n\n* History of ejection fraction less than 50% diagnosed by echocardiography\n* Diagnosed cognitive impairment or dementia\n* The state of cardiovascular disease decompensation\n* Exacerbation of comorbidities\n* The presence of chronic diseases that may affect the results of the study: ischemic heart disease (unstable angina, stable effort angina III-IV grade, previous myocardial infarction), previous Ischemic\u002Fhemorrhagic stroke, severe valvular heart diseases, cardiomyopathy, myocarditis, uncontrolled bronchial asthma or chronic obstructive pulmonary disease, terminal chronic kidney disease requiring dialysis, implanted pacemaker (including cardiac resynchronisation device, or defibrillator), active cancer, history of chemotherapy or radiation therapy to the chest area","FEMALE",{"count":198,"type":22},100,"The primary purpose of this study is to evaluate possible association of some heterogeneous circulating biomarkers and anamnestic factors of pregnancy adverse course and outcomes with the prognosis of heart failure with preserved ejection fraction. The study population includes women aged 60-74 years with history of pregnancy with duration at least 20 weeks and diagnosed heart failure with preserved ejection fraction based on algorithm HFA-PEFF.\n\nThe following pregnancy complications are assessed on the initial visit: gestational hypertension, preeclampsia, gestation diabetes mellitus and recently introduced as cardiovascular disease risk factors preterm delivery, stillbirth, miscarriage. This information is collected through a questionnaire which additionally includes questions about menopause and the circumstances of its onset. The data about comorbidities, results of laboratory and instrumental tests is collected from medical records. After the interview short physical examination is performed to measure anthropometric data and objective signs of congestion. In addition, medical Research Council Scale survey is conducted to assess the subjective severity of shortness of breath and a six-minute walking test to objectively evaluate the heart failure functional class.\n\nAfter inclusion in the study blood sampling is performed to measure the concentration of a number of biomarkers which are recognized as prognostically significant in context of heart failure: high-sensitivity troponin I, soluble suppression of tumorigenicity 2 protein, heat shock protein 27, cystatin C. As part of the study echocardiography is also performed with evaluation of left ventricular global longitudinal strain and left atrial strain to assess systolic and diastolic myocardium function.\n\n12 months after the initial visit, participants are contacted by telephone. The data about newly diagnosed chronic non-communicable diseases, emergency hospitalization for any cause and major adverse cardiovascular events is collected. If there is no response from the research participant, the cause, including possible hospitalization or death, is determined by telephone contact with the participant's trusted person.",[201],"Heart Failure With Preserved Ejection Fraction (HFPEF)",[203,204,205,206,207,208,209,210,211,212,213],"Heart Failure with Preserved Ejection Fraction","Adverse Pregnancy Outcomes","Gestational Hypertension","Preeclampsia","Gestational Diabetes Mellitus","Heart Diseases","Cardiovascular Diseases","Heart Failure","Pregnancy Complications","Preterm delivery","Stillbirth","2025-01-27",{"date":216,"type":39},"2025-01-31",{"date":218,"type":39},"2024-11-15",{"date":139,"type":22},{"name":45,"class":46},""]